Kuvera makes mutual fund investments simpler and faster. To invest in Nippon India Pharma Growth Direct Plan, login to Kuvera and search for Nippon India Pharma Growth Direct Plan. You can also go to "Invest", select "All Mutual Funds" and scroll to Nippon India Pharma Growth Direct Plan. Click on this to check details on the fund's performance and fundamentals. Depending on your risk appetite and investment objective, select either the Monthly SIP or One time (Lump sum investment) option and complete the investment process.

Nippon India Pharma Growth Direct Plan has given 48.2% over the last 1 year , 14.9% over the last 3 years, 24.3% over the last 5 years and 18.1% since its inception.

Minimum SIP amount required for Nippon India Pharma Growth Direct Plan is INR 100.

Minimum lump sum amount required for Nippon India Pharma Growth Direct Plan is INR 5000.

Create an account on Kuvera to invest in over 5000 direct mutual funds from the leading AMCs in India. To start an SIP for Nippon India Pharma Growth Direct Plan online, follow the steps given below:

Step 1: Login to Kuvera and click on Invest and then select Mutual Funds.

Step 2: Search by name, or scroll to Nippon India Pharma Growth Direct Plan and click on it.

Step 3: Choose Monthly SIP and enter the SIP amount and date for every month.

Step 4: Complete the fund transfer and you are done!

You can explore SIP, STP and SWP tabs in your cart to see all the funds that have existing SIPs.

Redeeming mutual funds on Kuvera is fast and hassle-free. To redeem Nippon India Pharma Growth Direct Plan, just go to your portfolio on the Kuvera app or website, click on the "Redeem" option under Nippon India Pharma Growth Direct Plan, enter your desired amount, or check the "Yes" next to Redeem all units if you want to redeem your entire holding.

Yes, you can invest in Nippon India Pharma Growth Direct Plan IDCW on Kuvera through SIP and Lump sum options. Follow these steps to get started :

On Kuvera app :

Step 1: Login and click on Invest and All Mutual Funds.

Step 2: Click on Filter, select "Plan" type as "Dividend". You will see the IDCW plans.

Step 3: Select Nippon India Pharma Growth Direct Plan and choose Monthly SIP or One Time investment options.

On Kuvera website

Step 1: Login and click on Invest on the home screen, select Mutual Funds.

Step 2:Turn the toggle from "Growth" to "Dividend" and you will see the results of all the IDCW plans.

Step 3: Select Nippon India Pharma Growth Direct Plan and choose Monthly SIP or One Time (Lump sum) investment options.

Create an account on Kuvera to invest in over 5000 direct mutual funds from the leading AMCs in India. To start an SIP for Nippon India Pharma Growth Direct Plan online, follow the steps given below:

Step 1: Login to Kuvera and click on Invest and then select Mutual Funds.

Step 2: Search by name, or scroll to Nippon India Pharma Growth Direct Plan and click on it.

Step 3: Choose Monthly SIP and enter the SIP amount and date for every month.

Step 4: Complete the fund transfer and you are done!

You can explore SIP, STP and SWP tabs in your cart to see all the funds that have existing SIPs.

Expense ratio is the amount (in percentage) which is charged by the mutual fund as a fee for managing your investment. Expense ratio of Nippon India Pharma Growth Direct Plan is 0.92% as on 10/05/2024.

NAV is the market value of the securities/assets held by the mutual fund divided by the total number of units issued by it. In simple terms, it is the price of a unit of the mutual fund. NAV of Nippon India Pharma Growth Direct Plan is INR 468.99 as on 09/05/2024.

Nippon India Pharma Growth Direct Plan has assets under management worth INR 7133 Cr.

As per SEBI regulations, all mutual funds should indicate the level of risk involved with investing in the mutual fund. There are five levels of risk (a) Low: Principal at low risk, (b) Moderately Low: Principal at moderately low risk, (c) Moderate: Principal at moderate risk, (d) Moderately High: Principal at moderately high risk, (e) High: Principal at high risk. Risk category of Nippon India Pharma Growth Direct Plan is Very High Risk.

The top 10 holdings of the Nippon India Pharma Growth Direct Plan as on 10/05/2024 are Sun Pharmaceuticals Industries Ltd at 14.91%, Lupin Ltd at 8.40%, Cipla Ltd at 6.51%, Apollo Hospitals Enterprise Ltd at 5.79%, Dr Reddy's Laboratories Ltd at 4.75%, Gland Pharma Ltd at 4.40%, Divi's Laboratories Ltd at 4.36%, Zydus Lifesciences Ltd at 4.18%, J.B. Chemicals & Pharmaceuticals Ltd at 3.44%, Abbott India Ltd at 3.29% .

Nippon India Pharma Growth Direct Plan is an equity mutual fund and the capital gains made from it are taxed at the rate of 10% for long term gains (if you hold your units for 1 year or more) and at the rate of 15% for short terms gains (if you hold your units for less than a year).

Investment objective of the Nippon India Pharma Growth Direct Plan:

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

The category of the Nippon India Pharma Growth Direct Plan is Sectoral/Thematic.

Nippon India Pharma Growth Direct Plan is managed by Sailesh Raj Bhan and Kinjal Desai as on 10/05/2024.

Exit load is the fee/penalty which some of the mutual funds charge in case an investor decides to sell his/her mutual fund units within the exit load window. Exit load for Nippon India Pharma Growth Direct Plan is